The chronic lymphocytic leukemia antigen (cCLLa) as immunotherapy target: Assessment of LD50 and MTD of four ricin-based anti-cCLLa immunotoxins (ITs) in Balb/c mice

Leukemia and Lymphoma

Volumn 25, Issue 5-6, 1997, Pages 531-537

  Faguet, Guy B ^a   Agee, Julia F ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

CLL; Immunotherapy; Immunotoxins; LD50; MTD

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IMMUNOTOXIN; LEUKEMIA ANTIGEN; RICIN;

ARTICLE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; IMMUNOTHERAPY; LD 50; MAXIMUM PERMISSIBLE DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0030751922     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709039041     Document Type: Article

References (32)

1. Foon, K. A., Schroff, R. W., Bunn, P. A., Mayer, D., Abrams, P. G., Fer, M., Ochs, J, Bottino, G. C., Sherwin, S. A., Carlo, D. J. et al. (1984) Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia, Blood, 64, 1085.
2. Meeker, T. C., Lowder, J., Maloney, D. B., Miller, R. A., Thielmans, K., Warnke, R. and Levy, R. (1985). A clinical trial of anti-idiotype therapy for B-cell malignancy, Blood, 65, 1349.
3. Janson, D., Nissel-Horowitz, S., Sattler, M. and Rai, K. R. (1993). Complete and partial response in treatment of advanced refractory B-cell chronic lymphocytic leukemia using CAMPATH-1H, Blood, 82, 139a, (abstract).
4. Vitetta, E. S., Fulton, R. J., May, D., Till, M. and Uhr, J. W. (1987). Redesigning nature's poisons to create anti-tumor reagents, Science, 238, 1098.
5. Pastan, I., Willingham, M. C. and Fitzgerald, D. J. (1986). Immunotoxins, Cell, 47, 641.
6. Faguet, G. B. and Agee, J. F. (1993). Four ricin chain A-based immunotoxins directed against the common chronic lymphocytic leukemia antigen: In vitro characterization, Blood, 82, 536.
7. Hertler, A. A., Schlossman, D. M., Borowitz, M. J., Laurent, G., Jansen, F. K., Schmidt, C. and Frankel, A. E. (1988). A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia, J. Biol. Resp. Modif., 7, 97.
8. Dillman, R. O., Beauregard, D. L., Shawler, J. B., Halpern, S. E., Markman, M., Ryan, K. P., Baird, S. M. and Cluter, M. (1986) Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma, J. Biol. Resp. Modif., 5, 394.
9. Grossbard, M. L., Freedman, S. A., Ritz, J., Coral, F., Goldmacher, V. S., Eliseo, L., Specter, N., Dear, K., Lambert, J. M., Blatter, W. A. et al. (1992). Serotherapy of B-CLL neoplasms with anti-B4-blocked ricin: A phase I trial of daily bolus infusion, Blood, 79, 576
10. Vitetta, E. S., Stone, M., Amlot, P., Fay, J., May, R., Till, M., Newman, J., Clark, P., Collins, R., Cunningham, D., Ghetie, V., Uhr, J. W. and Thorpe, P. E. (1991). Phase I immunotoxin trial in patients with B-cell lymphoma, Cancer Res., 54, 4052.
11. Derocq, J. M., Casellas, P., Laurent, G., Ravel, S., Vidal, H. and Jansen, F. (1988). Comparison of the cytotoxic potency of T101 Fab, F(ab)2 and whole IgG immunotoxins, J. Immunol., 141, 2837.
12. Faguet, G. B. and Agee, J. F. (1987). Monoclonal antibodies against the chronic lymphocytic leukemia antigen cCLLa: characterization and reactivity, Blood, 70, 437.
13. Faguet, G. B., Agee, J. F. and Marti, G. E. (1992). CD5 and cCLLa expression in chronic lymphocytic leukemia (CLL): Demonstration of their relative prevalence and that of other common B-CLL markers, Leukemia & Lymphoma, 6, 335.
14. Faguet, G. B. and Agee, J. F. The chronic lymphocytic leukemia antigen (cCLLa) as immunotherapy target: Pharmacokinetics and biodistribution of two divalent, ricin-based immunotoxins in xenografted, athymic mice. Leukemia & Lymphoma, 25, 509-520.
15. Faguet, G. B. and Agee, J. F. (1988). Transplantation of human hairy cell leukemia in radiation-preconditioned nude mice: Characterization of the model by histological, histochemical, phenotypic and tumor kinetics studies, Blood, 71, 1511-1517.
16. Faguet, G. B. and Agee, J. F. (1993). A simple technique for the rapid enrichment of class and subclass hybridoma switch variants: A 1000-fold enrichment in half the time for half the cost, J. Immunol. Methods, 165, 217
17. Ghetie, M. A., May, R. D., Till, M., Uhr, J. W., Ghetie, V., Knowles, P. P., Relf, M., Brown, A., Wallace, P. M., Janossy, G., Amlot, P., Vitetta, E. S. and Thorpe, P. E. (1988). Evaluation of ricin-A-chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents form vivo therapy. Cancer Res., 48, 2610.
18. Weil, C. S. (1952). Tables for convenient calculation of median effective dose (LD50 or ED50) and instructions in their use. Biometrics, 8, 249-163.
19. Thompson, W. R. (1947). Approximation of chi-square by "probits" and by "logits", Am Stat Assoc., 41, 70-74.
20. Mordenti, J. (1985). Phamacokinetic scale-up Accurate prediction of human pharmacokinetic profiles from animal data, J. Pharmaceutical Sciences. 74, 1097-1099.
21. Mordenti, J. (1986). Man versus Beast: Pharmacokinetic scaling in mammals. J. Pharmaceutical Sciences, 75, 1028-1040.
22. Faguet, G. B., Agee, J. F. and Marti, G. E. (1992). Clone emergence and evolution in chronic lymphocytic leukemia: Characterization of the clinical, laboratory and immunophenotypic profiles in 25 patients, Leuk. Lymphoma, 6, 345.
23. Faguet, G. B. and Agee, J. F. (1989) Kinetics of the malignant clone during fludarabine treatment of chronic lymphocytic leukemia (CLL), Blood, 74, 274A.
24. Bourrie, B. J. P., Casellas, P., Blythman, H. E. and Jansen. J. K. (1986) Study of the plasma clearance of antibody ricin-A chain immunotoxins. Evidence for specific recognition sites on the A chain that mediate rapid clearance of the immunotoxin, Eur. J. Biochem., 155, 1.
25. 2 fragments in a xenograft model, Cancer Letters, 76, 31.
26. Fulton, R. J., Tucker, T. F., Vitetta, E. S. and Uhr, J. W. (1988). Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: Effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization, Cancer Res., 48, 2618.
27. Schlesinger, P. H., Doebber, T. W., Mandell, B. F., White, R., SeSchryver, C., Rodman, J. S., Miller, M. J. and Stahl, P. (1978). Plasma clearance of glycoproteins with terminal mannose and N-acetylglucosamine by liver non-parenchymal cells. Studies with ™D-glucosaminidase ribonuclease B and galacto-orosomucoid, Biochem. J., 176, 103.
28. Ramakrishnan, S. and Houston, L. L. (1985) Immunological and biological stability of immunotoxins in vivo as studied by the clearance of disulfide-linked pokeweed antiviral protein-antibody conjugates from blood, Cancer Res., 45, 2031-2036.
29. Worrell, N. R., Cumber, A. J., Parnell, G. D., Ross, W. C. J. and Forrester, J. A. (1986). Fate of an antibody-ricin A conjugate administered to normal rats, Biochem. Pharmacol., 35, 417.
30. Blakey, D. C., Watson, G. J., Knowles, P. P. and Thorpe, P. E. (1987). Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy-1.1 antibody. Cancer Res., 47, 947.
31. Thorpe, P. E., Detre, S. I., Foxwell, B. M., Brown, A. N. F., Skilleter, D. N., Wilson, G., Forrester, J. A. and Stirpe, F. (1985). Modifications of the carbohydrate in ricin with metaperiodate-cyanoborohydride mixtures. Effects on toxicity and in vivo distribution, Eur. J. Biochem., 147, 197.
32. Collins, J. M., Zaharko, D. S., Dedrick, R. L., Chabner, B. A. (1986). Potential roles for preclinical pharmacology in phase I clinical trials, Cancer Treat. Rep., 70, 73-80.